Navigation Links
New approach to sickle-cell disease shows promise in mice
Date:12/7/2009

A new genetic approach to treating sickle cell disease is showing promising results in mice, report researchers from Children's Hospital Boston. By inactivating a gene they previously discovered to be important in the laboratory, they were able to boost production of a healthy fetal form of hemoglobin in the mice, potentially compensating for the defective adult hemoglobin that causes red blood cells to "sickle" and obstruct blood flow.

The study was presented by first author Jian Xu, PhD, on Sunday, December 6, at the American Society for Hematology meeting in New Orleans, at a 3 p.m. Plenary Scientific Session.

Currently, there are only a limited number of therapies available for patients with sickle cell disease, the most common inherited blood disorder in the U.S., says senior study author Stuart H. Orkin, MD, of Children's Division of Hematology/Oncology, also David G. Nathan Professor of Pediatrics at Harvard Medical School.

Shortly after birth, babies switch from producing the fetal form of hemoglobin, the protein inside red blood cells that carries oxygen, to producing the adult form the type that is affected in sickle cell disease. It's long been known that people who retain the ability to produce fetal hemoglobin have much milder disease. In previous studies (http://www.childrenshospital.org/newsroom/Site1339/mainpageS1339P1sublevel485.html), the Children's researchers, with collaborators, found that a gene called BCL11A is involved in switching off fetal hemoglobin production in adults. Working with genetically engineered mice, they then explored whether that switch could be turned back on to alleviate the disease.

In embryonic mice, inactivation of the BCL11A gene led to a robust expression of gamma-globin (the long protein chains making up the fetal form of hemoglobin) during late gestation: more than 90 percent of the globin produced was of this fetal type. In adult mice (8-10 weeks old), inactivation of the BCL11A gene in the blood system resulted in more than a 1,000-fold increase in gamma-globin production in bone marrow erythroblasts (the precursors to red blood cells) as compared with control mice. This increase was rapid and persisted during the course of the experiments (up until the mice were 25 weeks old).

This line of research began with comprehensive gene association studies, published in 2008 with collaborators at the Broad Institute of Harvard and MIT (http://www.childrenshospital.org/newsroom/Site1339/mainpageS1339P1sublevel452.html). These studies, involving 1600 patients with sickle cell disease, identified five DNA sequence variants (altered strings of genetic code) that correlated with fetal hemoglobin levels. BCL11A, on chromosome 2, had the largest effect, and Orkin and Vijay Sankaran, an MD-PhD student working with Orkin, later demonstrated that this gene directly suppresses fetal hemoglobin production.

If these preliminary results in mice hold up in human studies, inactivating BCL11A may also help patients with thalassemia, another blood disorder involving abnormal hemoglobin, adds Orkin.


'/>"/>

Contact: Rob Graham
rob.graham@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert

Related medicine news :

1. Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu
2. Brandeis studies evaluate visionary approach to improving eyesight
3. TMJ and Chiropractic Care: An Overall Wellness Approach
4. Endologix Receives IDE Approval for Fully Percutaneous Approach to EVAR
5. Dallas Facial Plastic Surgeon Publishes Cutting-Edge Novel Approach To Facelift Technique
6. Avizents New TeamCOMP Approach Helps Ensure Lower Workers Comp Costs and Faster Claims Resolution
7. Regence Takes Community Approach to Provider Reviews
8. Depression in older cancer patients can be effectively treated with collaborative approach
9. Inventive combination of research approaches identifies new target for treating leukemia
10. New approach for the treatment of malignant brain tumors
11. Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press ... mothers. These illustrations show the diversity of the breastfeeding mothers, using bright ... range of sizes. These illustrations are also available on tote bags, notepads, smartphone ...
(Date:8/18/2017)... ... August 19, 2017 , ... Mr. Noppadon Pakprot, Deputy ... Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest ... for Tourism Products and Business at TAT said, “Thailand has long been recognized ...
(Date:8/18/2017)... ... August 18, 2017 , ... August ... “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance of ... individuals with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... consulting services and asset protection assistance to communities in North-Central West Virginia, is ... critical services to at-risk boys in the area. , The Chestnut Mountain Ranch ...
(Date:8/18/2017)... ... 2017 , ... The Golseth Agency, a Texas based insurance management and financial ... regional charity campaign organized to provide support to Christina Upchurch and her two children ... and her children returned from out of town to find her husband passed away ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017   Mostyn Law and Gulf Coast ... Houston, Texas . The Mostyn Law family has ... years. That is why Mostyn Law is partnering with ... to show its appreciation. Blood supplies are running low. ... short of hospital needs in August. That is why the blood ...
(Date:8/15/2017)... N.C. , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator ... rumored to be in the beginning stages of an IPO. ... on epilepsy medications with the average cost of a prescription epilepsy drug ... ... Another staggering figure is the fact ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
Breaking Medicine Technology: